Colombia Pharmaceuticals & Healthcare Report

Published 04 August 2015

  • 117 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
$1,295.00
Colombia Pharmaceuticals & Healthcare Report

BMI View: A growing burden of chronic diseases, along with the Colombian government's push toward improving its national healthcare system will ensure the country's retained appeal to multinational drugmakers and healthcare suppliers. Despite remaining concerns surrounding Colombia's counterfeit drug market, the country's overwhelming demand for medical access will keep health and medicine spending on a positive trajectory over the long term.

Headline Expenditure Projections

  • Pharmaceuticals: COP8,643bn (USD4.3bn) in 2014 to COP9,110bn (USD3.6bn) in 2015; +5.4% in local currency terms. F orecast revised upward from Q 2 15 due to historical data.

  • Healthcare: COP53,417bn (USD26.7bn) in 2014 to COP57,414bn (USD22.4bn) in 2015; +7.5% in local currency terms. Forecast revised upward from Q 2 15 due to historical data.

Risk/Reward Index

In our Q415 regional Risk/Reward Index, Colombia has maintained seventh place out of 19 markets surveyed in the Americas region. The country's overall Risk/Reward score was 50.3, just above the regional average of 48.7. Colombia boasts above-average Rewards and Risks, although we caution that the country's intellectual property regime will continue to represent barriers to multinational involvement. Nevertheless, Colombia will continue to be of interest from a longer term point of view, not least on account of its substantial population numbers.

Key Trends and Developments

July

  • A commission of German experts, led by Parliamentarian Karl Lauterbach, visited Colombia to share their expertise on their home country's social security system. The delegation participated in a forum titled 'Germany Colombia: similar health systems, a lot to learn,' an initiative of Colombia's health and social protection ministry.

June

  • Colombia's Ministry of Health is set to release additional funds worth USD50bn to expand hospital infrastructure in the country in H215, according to Deputy Minister of Public Health and Service Fernando Ruiz...

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Colombia 2011-2019)
17
Healthcare Market Forecast
18
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Colombia 2011-2019)
20
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Colombia 2011-2019)
21
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Colombia 2011-2019)
22
Prescription Drug Market Forecast
23
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Colombia 2011-2019)
24
Patented Drug Market Forecast
25
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Colombia 2011-2019)
27
Generic Drug Market Forecast
28
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Colombia 2011-2019)
30
OTC Medicine Market Forecast
31
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Colombia 2011-2019)
33
Pharmaceutical Trade Forecast
34
Table: Pharmaceutical Trade Data And Forecasts (Colombia 2013-2019)
36
Table: Pharmaceutical Trade Data And Forecasts local currency (Colombia 2013-2019)
36
Key Risks To BMI's Forecast Scenario
37
Macroeconomic Forecasts
38
Economic Analysis
38
Table: Colombia - Key Economic Indicators
38
Table: Colombia - Private Consumption Forecasts
41
Table: Colombia - Government Consumption Forecasts
42
Table: Colombia - Fixed Investment Forecasts
43
Table: Colombia - Net Exports Forecasts
43
Industry Risk Reward Indices
44
Americas Risk/Reward Index - Q4 2015
44
Colombia Risk/Reward Index
50
Rewards
50
Risks
51
Market Overview
52
Industry Trends And Developments
54
Epidemiology
54
Healthcare Sector
56
Table: Healthcare Resources (Colombia 2009-2014)
59
Table: Healthcare Personnel (Colombia 2009-2014)
59
Table: Healthcare Activity (Colombia 2009-2014)
60
Research And Development
60
Table: Pharmaceutical Research and Science Centre (CECIF) Members, 2015
61
Clinical Trials
61
Regulatory Development
63
Intellectual Property Regime
64
Table: Colombia-US FTA Mechanisms Relevant To Intellectual Property
67
Pricing Regime
67
Reimbursement Regime
69
Competitive Landscape
72
Research-Based Industry
72
Table: Members Of Asociaci-n De Laboratorios Farmac-uticos De Investigaci-n (AFIDRO), 2012
73
Table: Leading Pharmaceutical Companies By Revenues, 2011 (COPmn)
74
Pharmaceutical Distribution
75
Table: Leading Pharmaceutical Importers/Wholesalers By Revenues, 2011
75
Pharmaceutical Retail
76
Company Profile
78
GlaxoSmithKline
78
Laboratorios Bussi-
81
Laboratorios Genfar SA
84
Lafrancol
87
Merck & Co
90
Novartis
93
Pfizer
96
Sanofi
99
Tecnoqu-micas
102
Demographic Forecast
105
Table: Population Headline Indicators (Colombia 1990-2025)
106
Table: Key Population Ratios (Colombia 1990-2025)
106
Table: Urban/Rural Population & Life Expectancy (Colombia 1990-2025)
107
Table: Population By Age Group (Colombia 1990-2025)
107
Table: Population By Age Group % (Colombia 1990-2025)
108
Glossary
110
Methodology
112
Pharmaceutical Expenditure Forecast Model
112
Healthcare Expenditure Forecast Model
112
Notes On Methodology
113
Risk/Reward Index Methodology
114
Index Overview
115
Table: Pharmaceutical Risk/Reward Index Indicators
115
Indicator Weightings
116

The Colombia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Colombia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Colombia pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Colombia, to test other views - a key input for successful budgeting and strategic business planning in the Colombian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Colombian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Colombia.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%